Results 251 to 260 of about 69,085 (277)

RAS-targeted therapies: is the undruggable drugged?

Nature Reviews Drug Discovery, 2020
Amanda R Moore, Frank McCormick, Shiva Malek   +2 more
exaly  

Uveal melanoma

Nature Reviews Disease Primers, 2020
Martine J Jager, Carol L Shields, Colleen M Cebulla   +2 more
exaly  

NRA Economic Planning

The American Historical Review, 1938
P. F. Brissenden, Charles Fredrick Roos
openaire   +1 more source

NRAS Gene

2020
openaire   +1 more source

NRA Conference

Journal of Visual Impairment & Blindness, 1956
openaire   +1 more source

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Lancet Oncology, The, 2013
Paolo A Ascierto, Dirk Schadendorf, Paola Queirolo   +2 more
exaly  

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Lancet Oncology, The, 2017
Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto   +2 more
exaly  

NRA

2012
openaire   +1 more source

The NRA:

2019
openaire   +1 more source

Targeting RAS–ERK signalling in cancer: promises and challenges

Nature Reviews Drug Discovery, 2014
Poulikos I Poulikakos
exaly